Michael Radonich, M.D.
NPI 1053404681 · Specialist · Los Alamitos, CA
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1053404681
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- A76286 (CA)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
10,135 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Pathology Examination of Tissue Using a Microscope, Intermediate Complexity88305 | 3,118 | $61 |
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 1,623 | $7 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 979 | $86 |
| Destruction of Cancer Skin Growth of Scalp, Neck, Hands, Feet, Or Genitals, 1.1-2.0 Cm17272 | 610 | $127 |
| Destruction of Cancer Skin Growth of Face, Ears, Eyelids, Nose, Lips, Or Mouth, 0.6-1.0 Cm17281 | 551 | $123 |
| Destruction of Cancer Skin Growth of Face, Ears, Eyelids, Nose, Lips, Or Mouth, 1.1-2.0 Cm17282 | 530 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 13 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Triamcinolone Acetonide | 106 | 72 |
| Doxycycline Hyclate | 84 | 40 |
| Ketoconazole | 60 | 30 |
| Metronidazole | 41 | 17 |
| Valacyclovir Hclbrand: Valacyclovir | 37 | 16 |
| Mupirocin | 36 | 31 |
| Fluocinonide | 34 | 19 |
| Clobetasol Propionate | 30 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$150 across 10 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-10-02
- Last updated
- 2007-07-08
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.